Get the Stockscreener App
4.3653
1.16%
0.0553
Ironwood Pharmaceuticals Inc stock is traded at $4.3653, with a volume of 789.70K.
It is up +1.16% in the last 24 hours and up +12.95% over the past month.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
See More
Previous Close:
$4.31
Open:
$4.31
24h Volume:
789.70K
Relative Volume:
0.33
Market Cap:
$721.27M
Revenue:
$361.51M
Net Income/Loss:
$102.18M
P/E Ratio:
7.3072
EPS:
0.5974
Net Cash Flow:
$112.21M
1W Performance:
+7.65%
1M Performance:
+12.95%
6M Performance:
-8.79%
1Y Performance:
+323.30%
1-Day Range:
$4.23
$4.4099
1-Week Range:
$3.96
$4.505
52-Week Range:
$1.01
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
4.365 | 712.18M | 361.51M | 102.18M | 112.21M | 0.5974 |
TAK
Takeda Pharmaceutical Co Adr
|
17.36 | 56.30B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.54 | 42.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.58 | 42.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.43 | 30.49B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
506.25 | 21.43B | 3.17B | 1.29B | 1.01B | 27.09 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Jeffrey Silber Net Worth (2026) - GuruFocus
Bank of America Corp DE Sells 2,838,753 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - marketbeat.com
Ironwood Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake - Stock Titan
Dimensional Fund Advisors LP Raises Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - marketbeat.com
Ironwood Pharmaceuticals (IRWD) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownTime to Sell? - marketbeat.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded to Buy Rating by Wall Street Zen - marketbeat.com
State Street Corporation (NYSE: IRWD caretaker) holds 5.4% of Ironwood common stock - Stock Titan
Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pacer Advisors Inc. Makes New $3.98 Million Investment in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call High - GuruFocus
Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed? - Yahoo! Finance Canada
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ... - Yahoo Finance
IRWD Looks 15.8% Undervalued on GF Value™ as Debt Reduction Effo - GuruFocus
Ironwood Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
Ironwood Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-08-06 - Seeking Alpha
Is Ironwood Pharmaceuticals (IRWD) Undervalued After Q2 Earnings - GuruFocus
IRWD: LINZESS sales surged and guidance was raised as apraglutide advanced in phase III trials - TradingView
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates - Yahoo Finance
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Ironwood Raises 2026 Guidance After Q2 Revenue Hits $113 Million - Quiver Quantitative
BRIEF-Ironwood Pharmaceuticals Q2 Revenue USD 113.041 Million Vs. IBES Estimate USD 114.8 Million - TradingView
Press Release: Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results - Moomoo
Segall Bryant & Hamill LLC Buys New Position in Ironwood Pharmaceuticals, Inc. $IRWD - marketbeat.com
Lazard Asset Management LLC Sells 710,256 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - marketbeat.com
Q2 2026 Ironwood Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Large Volume IncreaseWhat's Next? - marketbeat.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to "Hold" at Zacks Research - MarketBeat
IRWD Rises As Ironwood Advances Apraglutide And Shifts R&D Leadership - StocksToTrade
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 8.7%Should You Buy? - MarketBeat
Ironwood Pharmaceuticals to host Q2 2026 investor update call - scanx.trade
Ironwood Pharmaceuticals Inc (IRWD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BlackRock, Inc. (NASDAQ: IRWD) discloses 8.1% beneficial stake in Ironwood - Stock Titan
Ironwood Pharmaceuticals Inc (IRWD) Institutional Confidence - TradingKey
Return on assets % of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76 - TradingView
Total operating expenses of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76 - TradingView
Ironwood Pharmaceuticals Inc (IRWD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – BX:I76 - TradingView
Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – SWB:I76 - TradingView
Ironwood Pharmaceuticals Inc (IRWD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IRWD|Ironwood Pharmaceuticals Inc|Price:3.910|Chg%:+0.200 - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IRWD|Ironwood Pharmaceuticals Inc|Price:3.710|Chg%:-0.080 - TradingKey
Ironwood Pharmaceuticals Inc (I76.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
IRWD: Ironwood Pharmaceuticals IncOrdinary SharesClass A Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Ironwood Pharmaceuticals (IRWD) grants 137,036-share RSU new-hire award to CMO - Stock Titan
Ironwood Pharmaceuticals (IRWD) Jefferies 2024 Global Healthcare Conference Summary - Quartr
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating - Moomoo
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.71%
1.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):